Abstract 1359: Is Fish Consumption Adequate to Reach AHA Goals in Clinical Practice?
BACKGROUND: Omega-3 fatty acids have been shown in epidemiological and clinical trials to reduce the incidence of cardiovascular disease (CVD). In 2002 the American Heart Association (AHA) published recommended guidelines for the consumption of fatty fish/omega-3 fatty acids (O3FA) in patients ‘at risk’, with preexisting coronary artery disease (CAD), and healthy individuals. Prospective secondary prevention studies suggest that O3FA supplementation ranging from 0.5 to 1.8 g/d can significantly reduce subsequent cardiac and all-cause mortality. The AHA guideline for patients ‘at risk’ for CVD is to have at least 2 servings of fatty fish per week and for patients with documented CAD to have 7 gram of O3FA per week. We hypothesize that despite recommended guidelines, the dietary intake of O3FA would not meet the recommended levels without supplementation in an outpatient population that is ‘at risk’ or with known CAD.
METHODS: 231 consecutive patients with CAD (n=126) or ‘at risk’ for CVD (n=105) were evaluated in an outpatient academic cardiology office practice. These patients completed a questionnaire that detailed the following: quantity and type of fish, frequency of consumption, and use of dietary supplementation of O3FA. With this data we then calculated the quantity of O3FA intake in grams/week to compare with AHA recommendations.
RESULTS: Our findings demonstrated that in the group of patients ‘at risk’ for CVD not taking supplements (n=67) averaged 1.3 grams of O3FA per week, while those at risk for CVD who were taking supplements (n=38) averaged 8.8 grams of O3FA per week. In the group of patients with CAD not taking supplements (n=81) averaged 1.3 grams of omega 3 fatty acids per week, while those with CAD using supplements (n=45) averaged 10.4 grams O3FA per week.
CONCLUSION: Our data shows that patients at risk for CVD (1.3 gm/wk) and with CAD (1.3 gm/wk) do not meet the AHA recommended intake of O3FA of 2 servings/wk and 7 gm/wk respectively. Patients taking supplemental O3FA ‘at risk’ for CVD (8.8 gm/wk) and with CAD (10.4 gm/wk) exceeded recommended intake. Therefore we conclude that in out outpatient population of ‘at risk’ for CVD and with documented CAD generally do not reach the recommended AHA guidelines without the aid of supplemental O3FA.